Anabolic steroid-induced hypogonadism : diagnosis and treatment / Cyrus D. Rahnema, Larry I. Lipshultz, Lindsey E. Crosnoe, Jason R. Kovac, Edward D. Kim. - (Fertility and Sterility 101 (2014) 5 (1 May); p. 1271-1279)
- PMID: 24636400
- DOI: 10.1016/j.fertnstert.2014.02.002
Abstract
Objective: To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management.
Design: Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria.
Setting: Not applicable.
Patient(s): Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS.
Intervention(s): History and physical examination followed by medical intervention if necessary.
Main outcome measures(s): Serum testosterone and gonadotropin levels, symptoms, and fertility restoration.
Result(s): Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators.
Conclusion(s): Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.
